US Nuclear Targets Multi Billion Dollar Medical Radioisotope Shortage

DENVER, CO / ACCESSWIRE / June 11, 2018 / US Nuclear Corp. (OTC PINK: UCLE) management recently delivered another quarter of record growth, and have embarked on a multi-year plan to increase their share in the multi-billion dollar medical radioisotope market with the recent signing of a definitive agreement with MIFTEC industries.

The agreement formally appoints US Nuclear as the exclusive manufacturer of MIFTEC’s medical isotope generators for North America and Asia. MIFTI (parent company of MIFTEC) has developed Nuclear Fusion’s staged Z-pinch fusion technique which addresses the dire global shortage of medical radioisotopes while producing them at a fraction of the cost of current methods.

Dangerous Shortfall of Medical Radioisotopes

The medical isotope market is quite vast and encompasses both the diagnostic side of medicine (imaging and organ function) and the treatment side, where they are used primarily to weaken or destroy targeted cancer cells.

The current market is underserved to the tune of over $7 billion annually. Existing methods of production cost hundreds of millions of dollars to build, and up to a decade of construction time to complete. Currently, there are six government-owned nuclear research reactors in the world, none of which are located in the United States. The average age of these reactors is 53 years, with the licenses on four of the six reactors expiring within the next 10 years. Expansion of any of these existing facilities is cost prohibitive.

The United States accounts for half of the worldwide market for radioisotopes, with over 50,000 Americans each day depending on a resource whose supply chain can be described as precarious at best. Due to the rapid decay of the molybdenum-99 isotopes, they become useless in a matter of days. A senior director at Lantheus Medical Imaging has vividly described the entire process as “running through the desert with an ice cream cone”.

Advantages of Z-Pinch Method Used By MIFTI

MIFTI’s fusion approach provides a solution to a critical healthcare problem. The Z-Pinch process produces these isotopes faster, more efficiently, and at a fraction of the cost of the current process. The unit is small enough that the radioisotope generators could be placed at the actual hospitals, where the precious minutes of their half-life are not ticking off in international transport. This method poses no serious radiation risk, allowing for the decentralized production of the radioisotopes.

The fuel used by MIFTI in a staged Z-Pinch unit is extracted from seawater, meaning fuel supply is not an issue. This method also has enormous advantages with regards to nuclear waste. Where conventional nuclear reactors create dangerous nuclear waste that needs to be stored on geologic time scales, the Z-Pinch method creates little to no waste.

US Nuclear Has Been Doing This For Over 70 Years

For most companies, expanding into a $17B industry would seem like an ambitious goal, but US Nuclear Corp.’s seasoned management has been completing projects with the likes of the US Air Force, Los Alamos National Lab, Sandia and Jefferson National Labs for the better part of 50 years, lending confidence to their shareholders. Robert Goldstein, CEO of US Nuclear Corp. has been in the radiation industry since 1972 and has a degree from MIT in Physics and from Stanford University in Engineering. In fact, Technical Associates, the first division of US Nuclear Corp, started as a spin-off of the Manhattan project all the way back in 1946 in an effort to build equipment that would help protect the health and safety of the physicists from radiation.

Conclusion

With the recent signing of an exclusive agreement with MIFTEC, US Nuclear is very well positioned to capitalize on the medical radioisotope market projected to reach $17 billion by 2021. The company’s Z-Pinch technique generates radioisotopes faster, cheaper, and safer than all current production methods. Given the well-documented shortage of these isotopes and the deteriorating conditions of the facilities currently producing them, investors will want to take note of the significant upside potential of US Nuclear in the coming months.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as ”expects,” ”will,” ”anticipates,” and ”estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief ”snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.

SOURCE: US Nuclear Corp.

ReleaseID: 502139